Oregovomab (marketed under the trade name OvaRex) is a mouse monoclonal antibody it binds to the antigen CA125, a carbohydrate antigen. It is designed for the treatment of ovarian cancer.[1]
This drug was developed by AltaRex Corp.
References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Oregovomab, American Medical Association.
You must be logged in to post a comment.